Jul 31, 2025 3-5pm ET
Thursday on The Robert Scott Bell Show:
Hour 1
Special Guest: Jonathan Emord
For the past 37 years, Jonathan W. Emord has litigated against the federal bureaucracy, winning over and over again. Ron Paul calls Jonathan “an expert in constitutional theory and history” and “an expert litigator with a long string of legal victories over the federal bureaucracy.” George Noory calls him “a Knight in Shining Armor” and “a warrior out to save our rights.” Congressmen Dan Burton and John Doolittle describe him as “an intellectual warrior for the rights and freedoms of people in America.” Jonathan has a unique, detailed knowledge of the federal bureaucracy, the deep state. He knows how to defeat it. Jonathan graduated from the University of Illinois (BA, political science and history, 1982) and DePaul University College of Law (JD, 1985). He served as an attorney in the Federal Communications Commission during the Reagan administration. A leading constitutional law and litigation expert, he is the author of five critically acclaimed books. He has won more cases against the Food and Drug Administration in federal court than any other attorney in American history, earning him the nickname “FDA Dragon Slayer.” He is a columnist for Townhall.com, PJ Media.com, Americangreatness.com, and the U.S.A. Today Magazine. He frequently appears on national radio and television programs. He is married to Sheryl Emord, and they have two children, twins Justice and Angelica. They reside in Clifton, Virginia.
RFK Jr. Seeks Extra Time to Explore ‘Early Resolution’ in Vaccine Safety Lawsuit Children’s Health Defense (CHD) has filed a federal lawsuit on behalf of attorney Ray Flores, targeting Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. for failing to comply with the National Childhood Vaccine Injury Act of 1986. The suit alleges that Kennedy, like every HHS Secretary before him, has not fulfilled two core legal obligations: forming a National Vaccine Safety Task Force and submitting biennial reports to Congress on improvements to vaccine safety. According to the complaint, these mandates were designed to ensure transparency and continuous improvement in childhood vaccine oversight, especially given the federal liability shield granted to vaccine manufacturers under the law. Over 100 days into his term, Kennedy has not acted on these requirements, prompting the lawsuit, which seeks injunctive relief to compel compliance. Despite this, Flores and CHD have filed a joint motion requesting a two-week extension in proceedings to explore a potential early resolution out of court. The plaintiffs say this is not a delay tactic but an opportunity to resolve the issue cooperatively and efficiently. If the effort fails, they intend to proceed fully with the suit to ensure federal accountability. The case highlights mounting tension between Kennedy’s public vaccine safety reform agenda and the statutory obligations his office is accused of ignoring, with broader implications for how health policy is enforced in the post-COVID era.
Pure Political Pomp: Cabal of Vaccine Stakeholders File Bogus Lawsuit Against Kennedy, HHS A coalition of vaccine manufacturers, health institutions, and pro-vaccine stakeholders has filed a lawsuit against Health Secretary Robert F. Kennedy Jr. and the Department of Health and Human Services, alleging that Kennedy’s policies undermine public health infrastructure. The suit claims Kennedy has compromised vaccine safety standards by dismissing established advisory committees and replacing them with allies aligned with his personal views. Plaintiffs allege that these actions create conflict of interest and threaten immunization programs. Critics of the suit dismiss it as politically motivated, arguing that it reflects resistance to Kennedy’s challenge of entrenched pharmaceutical influence rather than legitimate legal grievance. Supporters of Kennedy label the effort as part of the “medical industrial complex” attempting to protect its dominance. The case is being filed in federal court and pledges legal pressure to halt Kennedy’s restructuring, requesting injunctions and financial damages. Observers view the lawsuit as emblematic of broader tension between pro‑vaccine institutions and MAHA-aligned leadership seeking to disrupt FDA–CDC consensus.
New Guidelines Will Allow Federal Workers To Express Religious Beliefs At Workplace The Trump administration has issued new federal policy guidance granting expanded rights for religious expression at work. According to a memo from the Office of Personnel Management, federal employees can display religious items such as jewelry, engage in prayer groups during breaks, form faith-based discussion circles, and even persuade coworkers of their beliefs—provided it is not harassing or disruptive. Supervisors are also permitted to invite employees to religious events or lead prayers with the public, like park tours or veteran care. The memo emphasizes First Amendment protections under Title VII of the Civil Rights Act and frames this as restoring religious liberty in federal service. Critics warn the guidance may blur church‑state boundaries, pressure nonbelievers, and create workplace tension. Supporters say it’s a necessary correction to perceived bias against religious employees in federal employment. The shift signals a broader ideological push to elevate faith presence in governmental settings and institutional daily life.
End of the Woke: Detroit’s Big Three Automakers Bring Back Gas Guzzlers Americans Love Breitbart highlights a shift in the U.S. auto industry as GM, Ford, and Stellantis pivot away from electric vehicles toward renewed production of larger, gas-powered trucks and SUVs. Economic analysts argue this return reflects carmakers aligning with consumer demand and rejecting what they describe as brief trends shaped by left-wing “woke” ideology. According to commentary on the Alex Marlow Show, corporations have realized that broadly appealing policies such as DEI and Green New Deal initiatives do not reflect mainstream America and mischaracterize broader consumer values. The article frames this pivot as a broader cultural reprisal: rebuilding traditional American car culture and tapping into nostalgia for “real” vehicles. The segment suggests Detroit’s Big Three are prioritizing market-driven decision making over ideological pressure, with executives doubling down on profitable combustion vehicles. While the electric shift is not claimed dead, Breitbart asserts that legacy automakers are re-embracing internal combustion models to match customer preference and boost margins. The broader message positions this trend as symbolic of a wider rejection of progressive corporate agendas, signaling a resurgence of blue‑collar, Americana identity that appeals to everyday consumers rather than activist-focused policy narratives.
Exclusive–Bessent Warns of ‘Caracas on the Hudson’ as Young Voters Turn to Socialism: ‘They’re Disillusioned with the System’ Financial strategist Travis Bessent warns that demographic shifts in New York City are fueling a leftward swing among young voters, raising fears of a socialist takeover reminiscent of troubled Latin American cities—“Caracas on the Hudson,” he cautions. His analysis attributes the trend to economic frustration: wage stagnation, rising debt, and lack of generational wealth are driving disillusionment with capitalism. Bessent claims that candidates promising radical economic restructuring, public ownership, and wealth redistribution are gaining traction among voters aged 18–35. He argues this shift threatens fiscal stability and erodes the traditional bipartisan political center in urban America. The piece stresses that turning public services and utilities into state-owned entities would damage infrastructure, deter investment, and replicate mismanagement often seen in Caracas. Bessent warns New York may become a testing ground for national socialist policies unless moderates reclaim the political center. While critics view the alarm as hyperbolic, supporters see growing youth support for broader public benefit initiatives—including expanded rent control and universal health care—as an early warning sign. The article frames the shift as reflective of broader generational impatience with inequality, cautioning that failure to adapt or communicate market-based solutions may fuel irreversible political realignment in major urban centers.
Zohran Mamdani Beats Out All NYC Mayoral Candidates Combined—New Poll A recent CITY USA poll shows progressive City Council member Zohran Mamdani leading in New York City’s 2025 mayoral primary, outperforming all other contenders combined. Garnering approximately 35 percent support, Mamdani polled ahead of established figures including former Governor Andrew Cuomo and incumbent Mayor Eric Adams. The poll attributes Mamdani’s rise to his strong standing among Democratic-leaning liberals and younger voters, with support peaks in key boroughs like Brooklyn and Queens. His platform emphasizing affordable housing, tenant protections, and educational reform resonates with voters frustrated by high living costs and perceived political inertia. Though Cuomo and Adams remain recognizable within the electorate, both face declining favorability and skepticism over leadership credibility, particularly regarding misconduct investigations and perceived bureaucratic stagnation. Mamdani’s surge signals growing appetite for outsider and grassroots-driven candidacies in urban politics. However, most voters remain undecided, and feasibility questions persist around ballot access, fundraising, and campaign organization. The article notes that if current trends hold, Mamdani could emerge as a major voice of progressive urban governance. But victory is not assured; the field remains open, and final outcomes will hinge on voter turnout and debate performance leading up to the primary.
Hour 2
Mainstream Media Admits COVID Shots “Saved Far Fewer Lives Than First Thought” Recent recalculation by researchers revises the estimated global impact of COVID-19 vaccines: instead of an initial projection of 20 million lives saved, the revised estimate places lives saved at approximately 2.5 million worldwide across four years of mass vaccination. The updated modeling reflects real-world data during the Omicron era, with declining virus severity and increasing natural immunity. The analysis found one death prevented for every 5,400 vaccine doses administered. Most of the benefit was concentrated among older adults, particularly those aged 60 and above, and was accrued before COVID infection rather than post-infection treatment. These findings prompt mainstream outlets to temper earlier narratives about vaccine efficacy and mortality prevention. Public health advocates argue that even 2.5 million prevented deaths constitute a substantial achievement, while critics assert that early overestimations contributed to overstated public messaging. The revised figures highlight the evolving nature of pandemic data and reinforce the need for updated policy communication and public expectations in light of updated scientific evidence.
Study Finds Elevated Liver Enzymes in Healthy Adults Using CBD A recent randomized trial overseen by FDA researchers examined 201 healthy adults who consumed cannabidiol (CBD) at a dose of approximately 5 mg per kilogram of body weight twice daily for 28 days—mirroring intake levels common in over-the-counter products. Results showed that roughly 5.6 percent of CBD users experienced liver enzyme elevations—specifically alanine aminotransferase or aspartate aminotransferase levels exceeding three times the upper limit of normal—while none in the placebo group exhibited this change. Seven subjects were withdrawn from the study due to potential drug-induced liver injury. Although the trial did not report symptoms of hepatic distress, the enzyme elevations suggest subclinical liver stress from moderate CBD use. The data reinforce earlier findings that CBD can inhibit cytochrome P450 enzymes, affecting liver metabolism. Investigators emphasize caution for individuals with pre-existing liver conditions or concurrent medication use. The study concludes that routine screening for liver enzyme levels should be considered in clinical settings when CBD use is documented. Given the prevalence of unregulated CBD consumption, researchers recommend further safety evaluation, clearer dosage guidelines, and public awareness on potential hepatic risks associated with daily use.
Even Low Doses of CBD May Cause Harm to the Liver in Some People, FDA Study Finds A recent FDA-commissioned randomized clinical trial involving 201 healthy adults has revealed that even low doses of CBD—comparable to amounts commonly found in over-the-counter products—can trigger liver injury in approximately 5.6% of individuals. Participants who consumed about 5 mg per kg of body weight twice daily for four weeks showed elevated liver enzymes—specifically alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above three times the upper limit of normal—while none of the placebo group exhibited such elevations. Seven participants were discontinued from the study due to concerns of drug-induced liver injury despite lacking symptoms. Only one participant reported mild symptoms, like fatigue and nausea, underscoring how silent liver inflammation can go unnoticed unless routine blood monitoring is performed. A commentary from Rambam Health Care confirmed that most affected individuals had no symptoms, reinforcing the study’s warning that CBD use may be silently hepatotoxic in a small subset of users. Experts emphasize that liver enzyme elevations reversed after stopping CBD, but the findings carry broader implications: unregulated CBD use—even at modest doses—can pose a risk, especially for those with preexisting liver conditions or concurrent medication use. Medical professionals are urged to screen for liver enzyme abnormalities when patients report CBD use and to counsel on dosage limitations. The study strengthens earlier concerns from FDA warnings that CBD may affect liver metabolism and interact with other medications—further complicating its safety profile for widespread, unsupervised consumption.
Trump’s Health Data Grab: Big Tech, AI, and the Centralized Medical Surveillance State No One Asked For The Trump administration has unveiled a sweeping initiative to create a centralized digital health ecosystem by partnering with tech giants and healthcare corporations, effectively enabling Americans to consolidate personal medical records across platforms like Google, Apple, Amazon, and UnitedHealth Group. Branded under an event titled “Making Health Technology Great Again” and overseen by the Centers for Medicare & Medicaid Services (CMS), the program is touted as an overdue modernization of fragmented healthcare systems—promising improved management of chronic conditions like diabetes and obesity via AI tools, conversational assistants, and wellness apps. However, digital privacy advocates warn that reliance on private tech firms—many not governed by HIPAA—may expose sensitive patient data to unauthorized access, monetization, and misuse beyond healthcare purposes. Critics point to prior controversies involving governmental use of health data for immigration enforcement as proof of potential mission creep. While participation in the system remains opt-in, significant transparency gaps persist regarding data governance, algorithmic biases, and third-party accountability. Despite its promise of interoperability and patient empowerment, the initiative has drawn sharp scrutiny for elevating corporate actors in control of health data infrastructure—raising questions about privacy, equity, and public oversight in the emerging digital care paradigm.
Why Today’s Young Adults Are 4 Times More Likely To Have Rectal Cancer New generational analysis shows Americans born around 1990 face a fourfold increase in rectal cancer risk—and a twofold increase in colon cancer risk—compared to those born in 1950. From 2010 to 2019, early-onset gastrointestinal cancers rose 14.8 percent, disproportionately affecting individuals under 50. Contributing factors include rising obesity rates, poor diet, processed foods, and non-alcoholic fatty liver disease. Studies using national cancer registries confirm increasing incidence rates in people 20–39 years old, with left-sided and rectal tumors appearing in 60–90 percent of cases. While traditional risk models emphasize family history—only 10–30 percent of cases under age 50 are associated with known hereditary syndromes—the majority are sporadic and linked to lifestyle and environmental exposures. Experts warn of delayed diagnosis and more advanced disease at presentation in younger patients, resulting in greater treatment burden and financial toxicity. Global data from multiple high-income countries reveal a steady rise in early-onset colorectal cancer, even as rates decline among older populations. The shift has prompted recommendations to lower screening age to 45 and increase awareness of warning signs like rectal bleeding, bowel habit changes, and unexplained weight loss. Physicians urge younger adults to seek evaluation promptly if symptoms appear.
Question of The Day!
Any recommendations for a gi bleed? I’ve been doing aloe vera protocol and cangest everyday for 2 months. It hasn’t resolved itself. Does it take more time? Anything else I can do? Thanks
Nicole
Welcome to another Homeopathic Hits segment on The Robert Scott Bell Show!
Today we spotlight Kalium Arsenicosum, a remedy that reaches deep into the body’s reserves—physically and emotionally.
Known for its impact on degenerative skin conditions, nervous exhaustion, and lingering respiratory weakness, Kalium Arsenicosum is a go-to for cases that seem stuck in decline. It supports restoration when both energy and resilience are fading fast.
Download the Information Sheet
Remember Friends, The Power to Heal is Yours!
